Tag: breast cancer liquid biopsy market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Breast Cancer Liquid Biopsy Market Growth From $1.02 Billion In 2026 To $1.75 Billion By 2030 At A CAGR Of 14.3%

The breast cancer liquid biopsy market has experienced substantial expansion recently. The market is forecast to expand from $0.89 billion in 2025 to $1.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. This past expansion was driven by factors such as the increasing incidence of breast cancer, the drawbacks of traditional tissue biopsies, breakthroughs in oncology diagnostics, heightened awareness regarding screening, and the broader availability of laboratory testing.

The breast cancer liquid biopsy market is poised for significant expansion in the foreseeable future. It is forecast to attain a valuation of $1.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This anticipated progress throughout the forecast period stems from the increasing adoption of precision oncology, the utilization of AI-based mutation analysis, the development of personalized treatment planning, an uptick in cfDNA testing, and the spread of decentralized cancer diagnostics. Key developments expected during this period encompass multi-biomarker blood-based testing, non-invasive cancer monitoring techniques, methods for tracking treatment response, early detection of recurrence, and individualized oncology diagnostics.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=36475185&type=smp&name=Breast%20Cancer%20Liquid%20Biopsy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Breast Cancer Liquid Biopsy Market Expansion Drivers: What’s Shaping Future Growth?

The rising incidence of breast cancer is expected to drive the expansion of the breast cancer liquid biopsy market. Breast cancer is a malignancy that develops in breast cells, typically in the milk-producing glands (lobules) or milk-carrying ducts. The increase in breast cancer cases is attributed to various factors including genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, lack of physical activity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy is utilized in treatment to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, facilitating real-time disease monitoring. It also aids in assessing treatment response, identifying therapy resistance, and detecting genetic mutations for targeted therapies. For instance, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, the number of new breast cancer cases is projected to climb to 319,750 in 2025, up from 313,510 cases in 2024. Thus, the increasing number of breast cancer cases is a key factor propelling the growth of the breast cancer liquid biopsy market.

Breast Cancer Liquid Biopsy Market Segment Analysis: What Are The Core Market Categories?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Breast Cancer Liquid Biopsy Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies in the breast cancer liquid biopsy market are concentrating on creating innovative products, such as companion diagnostics, to enable personalized treatment strategies by identifying patients who will benefit from particular therapies. These companion diagnostics leverage liquid biopsy technologies to detect biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that indicate how a patient might respond to treatment. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test to serve as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a treatment designed for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to employ the test for comprehensive genomic profiling, thereby identifying patients who may benefit from the targeted therapy. It signifies Guardant Health’s inaugural U.S. Food and Drug Administration (FDA) approval in the breast cancer field, expanding its contribution to precision oncology.

Breast Cancer Liquid Biopsy Market Leading Companies And Competitive Benchmarking

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

View The Full Breast Cancer Liquid Biopsy Market Report:

https://thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Breast Cancer Liquid Biopsy Market Largest Region By Revenue And Market Share

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Breast Cancer Liquid Biopsy Market From 2026 To 2030?

The breast cancer liquid biopsy market has experienced substantial expansion in recent years. Its growth is projected from $0.89 billion in 2025 to $1.02 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. The market’s historical development can be attributed to factors such as rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, and laboratory testing expansion.

The breast cancer liquid biopsy market is anticipated to experience substantial growth in the coming years. It is projected to achieve a value of $1.75 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.3%. This expansion during the forecast period is attributed to factors like the adoption of precision oncology, AI-based mutation analysis, personalized treatment planning, an increase in cfDNA testing, and the rise of decentralized cancer diagnostics. Significant trends expected during this period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, and personalized oncology diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which Drivers Are Advancing The Breast Cancer Liquid Biopsy Market Growth?

The rising incidence of breast cancer is anticipated to stimulate the expansion of the breast cancer liquid biopsy market moving forward. Breast cancer is defined as a malignancy originating in breast cells, frequently in the lobules (glands producing milk) or ducts (channels transporting milk to the nipple). The upward trend in breast cancer diagnoses stems from various contributors such as genetic susceptibility, disruptions in hormone levels, an older demographic, shifts in lifestyle, excess weight, alcohol intake, insufficient exercise, radiation exposure, and contaminants in the environment. In a therapeutic context, a breast cancer liquid biopsy serves to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) within the bloodstream, enabling continuous disease monitoring. This method assists in evaluating how patients respond to treatment, recognizing when therapies become ineffective, and pinpointing genetic alterations for specific, targeted treatments. For example, the American Cancer Society, a US-based nonprofit organization focused on cancer research, education, advocacy, and patient support, projects an increase in new breast cancer cases to 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the expanding number of breast cancer instances is propelling the growth of the breast cancer liquid biopsy market.

What Are The Major Segment Categories Within The Breast Cancer Liquid Biopsy Market?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Trends Are Influencing The Breast Cancer Liquid Biopsy Market?

Key companies operating in the breast cancer liquid biopsy market are prioritizing the creation of advanced products, such as companion diagnostics, to support personalized treatment strategies by identifying patients most likely to benefit from specific therapies. These companion diagnostics leverage liquid biopsy technologies to detect biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions, which indicate treatment responsiveness. For example, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test serves as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval empowers oncologists to utilize the test for comprehensive genomic profiling, thereby pinpointing patients who could benefit from the targeted treatment. It represents Guardant Health’s first U.S. Food and Drug Administration (FDA) approval in breast cancer, enhancing its involvement in precision oncology.

Which Key Players Are Active In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Access The Complete Breast Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Region Holds The Largest Share In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Breast Cancer Liquid Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Breast Cancer Liquid Biopsy Market Compare Between 2026 And 2030?

The breast cancer liquid biopsy market size has seen rapid expansion in recent years. It is anticipated to grow from $0.89 billion in 2025 to $1.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. The historical increase in this market can be attributed to several factors such as rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, and laboratory testing expansion.

The breast cancer liquid biopsy market is anticipated to undergo significant expansion in the coming years, with its size projected to reach $1.75 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.3%. This expansion during the forecast period is primarily due to factors like precision oncology adoption, AI-based mutation analysis, personalized treatment planning, growth in cfDNA testing, and decentralized cancer diagnostics. Prominent trends for this period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, and personalized oncology diagnostics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which Primary Drivers Are Impacting The Breast Cancer Liquid Biopsy Market Growth?

The increasing number of breast cancer cases is projected to drive the expansion of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that forms in the breast’s cells, typically within the lobules (milk-producing glands) or ducts (pathways that transport milk to the nipple). The growing occurrence of breast cancer is influenced by factors including genetic predisposition, hormonal imbalances, an aging demographic, changes in lifestyle, obesity, alcohol consumption, insufficient physical activity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy is employed in treatment to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, facilitating real-time disease monitoring. It plays a role in evaluating treatment effectiveness, detecting resistance to therapy, and pinpointing genetic mutations for targeted interventions. For instance, in 2025, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, the count of new breast cancer cases is anticipated to climb to 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the rise in breast cancer cases is propelling the growth of the breast cancer liquid biopsy market.

Which Segment Types Are Examined In The Breast Cancer Liquid Biopsy Market Segment Study?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Which Trends Are Shaping Growth In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are primarily focusing on the development of innovative products, such as companion diagnostics, to enable personalized treatment approaches by pinpointing patients who are likely to benefit from specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect crucial biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a treatment intended for advanced or metastatic breast cancer patients with ESR1 mutations. This approval empowers oncologists to use the test for comprehensive genomic profiling, thereby identifying patients who may be suitable candidates for the targeted therapy. It represents Guardant Health’s inaugural U.S. Food and Drug Administration (FDA) approval in the breast cancer field and enhances its contribution to precision oncology.

Which Players Are Part Of The Competitive Landscape Of The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Get The Full Breast Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Where Is The Breast Cancer Liquid Biopsy Market Most Concentrated Geographically?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Breast Cancer Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Breast Cancer Liquid Biopsy Market Evolve From 2026 To 2030?

The breast cancer liquid biopsy market size has seen rapid growth over recent years. It is projected to expand from $0.89 billion in 2025 to $1.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. This historical growth can be attributed to factors such as the rising incidence of breast cancer, the inherent limitations of tissue biopsy, breakthroughs in oncology diagnostics, increased public awareness regarding screening, and the broader expansion of laboratory testing services.

The breast cancer liquid biopsy market size is set to experience significant growth in the upcoming years. It is projected to expand to $1.75 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This anticipated growth is primarily driven by the increasing adoption of precision oncology, advancements in AI-based mutation analysis, personalized treatment planning, an uptick in cfDNA testing, and the expansion of decentralized cancer diagnostics. Notable trends expected during this period involve multi-biomarker blood-based testing, non-invasive methods for cancer monitoring, tracking treatment response, early recurrence detection, and personalized oncology diagnostics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Drivers Are Influencing The Breast Cancer Liquid Biopsy Market?

The rising incidence of breast cancer is anticipated to fuel the expansion of the breast cancer liquid biopsy market. Breast cancer originates in the breast cells, commonly in the lobules (milk-producing glands) or ducts (passages transporting milk to the nipple). This surge in cases is attributed to various factors such as genetic predisposition, hormonal imbalances, an aging demographic, altered lifestyles, obesity, alcohol intake, insufficient physical activity, radiation exposure, and environmental contaminants. In treatment, a breast cancer liquid biopsy serves to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, enabling real-time disease monitoring. This method assists in evaluating treatment effectiveness, identifying resistance to therapies, and pinpointing genetic mutations crucial for targeted treatments. For example, the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, projects new breast cancer cases to reach 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the expanding number of breast cancer cases is propelling the growth of the breast cancer liquid biopsy market.

Which Segment Areas Are Covered In The Breast Cancer Liquid Biopsy Market Analysis?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Key Developments And Trends Are Impacting The Breast Cancer Liquid Biopsy Market?

Leading companies active in the breast cancer liquid biopsy market are concentrating on creating innovative products, such as companion diagnostics, to enable personalized treatment methods by identifying patients who respond well to specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that signal treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test, which functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to employ the test for comprehensive genomic profiling, thereby pinpointing patients who could benefit from the targeted therapy. This achievement represents Guardant Health’s initial U.S. Food and Drug Administration (FDA) approval in the breast cancer field and enhances its role in precision oncology.

Which Global Companies Are Actively Competing In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Read the full breast cancer liquid biopsy market report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Breast Cancer Liquid Biopsy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the remote visualization workstations market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Breast Cancer Liquid Biopsy Market be in 2030 compared with 2026?

The breast cancer liquid biopsy market has expanded rapidly in recent years. It is projected to increase from $0.89 billion in 2025 to $1.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. This historical growth can be linked to factors such as the rising incidence of breast cancer, the drawbacks of tissue biopsy, progress in oncology diagnostics, enhanced awareness of screening, and the broadening of laboratory testing.

The breast cancer liquid biopsy market size is projected to experience substantial expansion in the coming years, anticipated to reach $1.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This growth during the forecast period is primarily driven by the increasing adoption of precision oncology, advancements in AI-based mutation analysis, the development of personalized treatment planning, the rising prevalence of cfDNA testing, and the expansion of decentralized cancer diagnostics. Key trends influencing the market in this period include multi-biomarker blood-based testing, the emergence of non-invasive cancer monitoring, enhanced treatment response tracking, improved early recurrence detection, and the growth of personalized oncology diagnostics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Drivers Are Guiding Growth Patterns In The Breast Cancer Liquid Biopsy Market?

The increasing prevalence of breast cancer cases is projected to stimulate the growth of the breast cancer liquid biopsy market moving forward. Breast cancer is a malignancy that develops in the cells of the breast, typically found in the lobules, which are milk-producing glands, or the ducts that transport milk to the nipple. The rise in breast cancer cases can be attributed to several factors, including genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, insufficient physical activity, exposure to radiation, and various environmental pollutants. During treatment, a breast cancer liquid biopsy is utilized to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, facilitating real-time monitoring of the disease. This method is beneficial for assessing treatment response, identifying resistance to therapies, and pinpointing genetic mutations for targeted interventions. For instance, data from the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, indicates that the number of new breast cancer cases is anticipated to climb to 319,750 in 2025, rising from 313,510 cases in 2024. Therefore, the upward trend in breast cancer cases is a significant factor driving the growth of the breast cancer liquid biopsy market.

Which Segments Are Driving Activity In The Breast Cancer Liquid Biopsy Market?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Trends Are Projected To Support The Growth Of The Breast Cancer Liquid Biopsy Market?

Leading firms within the breast cancer liquid biopsy market are prioritizing the creation of novel products, including companion diagnostics, to facilitate tailored treatment strategies by pinpointing individuals likely to respond to particular therapies. These companion diagnostics leverage liquid biopsy techniques to identify biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that signal responsiveness to treatment. As an illustration, in January 2023, Guardant Health Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy designed for advanced or metastatic breast cancer patients exhibiting ESR1 mutations. This authorization allows oncologists to employ the test for comprehensive genomic profiling, thereby identifying patients who could benefit from the specific targeted therapy. This represents Guardant Health’s first U.S. Food and Drug Administration (FDA) approval within the breast cancer field, thereby enhancing its contribution to precision oncology.

Which Major Firms Are Strengthening Their Position In The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Breast Cancer Liquid Biopsy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Breast Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Breast Cancer Liquid Biopsy Market From 2025 To 2034?

The market for breast cancer liquid biopsies has witnessed substantial recent expansion, projected to escalate from a value of $0.78 billion in 2024 to $0.89 billion in 2025, reflecting a compound annual growth rate of 14.2%. This previous period’s upward trajectory is essentially driven by progress in next-generation sequencing technologies, the rising incidence of breast cancer cases globally, an escalating need for diagnostic procedures that do not require invasive sampling, the wider acceptance of tailored medical treatments, and augmented financial support channeled into oncology research initiatives.

Anticipation surrounds the breast cancer liquid biopsy sector, projecting substantial expansion in the immediate future, with its market valuation set to reach $1.53 billion by 2029, expanding at a Compound Annual Growth Rate (CAGR) of 14.5%. This upward trajectory across the projection timeframe stems from several key factors, notably the progress in liquid biopsy assay technologies, a broader incorporation of these biopsies for initial cancer detection, the escalating need for continuous cancer surveillance, wider utilization within personalized cancer treatments, and greater capital allocation towards research and development activities for liquid biopsy solutions. Observably, prevailing currents influencing this market involve weaving artificial intelligence into the interpretation of liquid biopsy data, progress in sequencing methodologies at the single-cell level, creation of comprehensive multi-omics platforms for liquid biopsies, enhancements to the precision and accuracy of these tests, and the embrace of digital PCR techniques for identifying mutations with extremely high resolution.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are The Top Growth Drivers Impacting The Breast Cancer Liquid Biopsy Market Outlook?

Anticipated escalation in the incidence of breast cancer is slated to fuel the expansion of the market for breast cancer liquid biopsies moving ahead. This malignancy, originating within the breast tissues—commonly the milk-producing lobules or the ducts that transport milk towards the nipple—is seeing higher prevalence attributed to various risk elements such as hereditary tendencies, hormonal fluctuations, an aging demographic, shifts in daily habits, elevated body mass, alcohol intake, insufficient exercise, exposure to radiation, and environmental toxins. Liquid biopsies for this condition are employed in treatment protocols to identify cell-free tumor DNA (ctDNA) or circulating tumor cells (CTCs) present in the bloodstream, thus enabling continuous disease surveillance. This technology proves valuable for evaluating how well treatments are working, spotting the emergence of resistance to therapies, and pinpointing specific genetic alterations necessary for selecting personalized treatments. To illustrate this trend, projections from the American Cancer Society, a US organization focused on cancer research, advocacy, education, and patient assistance, indicate that new breast cancer diagnoses are set to climb to 319,750 in 2025 from 313,510 cases noted in 2024. Consequently, this upward trajectory in breast cancer diagnoses serves as a primary impetus for the development of the breast cancer liquid biopsy sector.

What Are The Major Segment Categories Driving The Breast Cancer Liquid Biopsy Market Growth?

The breast cancer liquid biopsymarket covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Which Trends Are Impacting The Breast Cancer Liquid Biopsy Market?

Key participants within the breast cancer liquid biopsy arena are directing their efforts toward creating novel offerings, notably companion diagnostics, with the objective of facilitating customized treatment regimens by distinguishing individuals responsive to particular therapeutic interventions. These companion diagnostics leverage liquid biopsy methodology to pinpoint crucial biomarkers, encompassing genetic alterations, cell-free tumor DNA (ctDNA), or protein signatures that signal potential efficacy of treatment. As an illustration, in the month of January 2023, Guardant Health Inc., a firm based in the United States specializing in biotechnology, secured authorization from the Food and Drug Administration (FDA) for its Guardant360 CDx assay, designating it as a companion diagnostic tool for Menarini Group’s ORSERDU (elacestrant), which addresses advanced or metastatic breast cancer cases harboring ESR1 mutations. This regulatory clearance permits medical professionals administering oncology care to deploy the test for thorough analysis of a patient’s genetic makeup, thus identifying those candidates most likely to gain advantage from this specific targeted medication, simultaneously representing Guardant Health’s inaugural FDA approval within the domain of breast cancer diagnostics in the US and broadening its influence within the field of precision cancer treatment.

Which Industry Leaders Are Driving Innovation Across The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Breast Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodie-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Breast Cancer Liquid Biopsy Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for liquid biopsy in breast cancer has experienced swift growth in recent years. Its worth, expected to rise from $0.78 billion in 2024 to $0.89 billion in 2025, signifies a compound annual growth rate (CAGR) of 14.2%. This sharp growth in the historic period is due to breakthroughs in next-generation sequencing (ngs), a higher incidence rate of breast cancer, an escalating demand for non-surgical diagnosis methods, a rising trend towards personalized medicine, and an increase in financial support for cancer research.

In the coming years, the breast cancer liquid biopsy market is anticipated to experience significant expansion, reaching $1.53 billion by 2029 at an annual compounded growth rate (CAGR) of 14.5%. This projected growth over the forecast period can be linked to several factors, such as advancements in liquid biopsy assays technology, increased use of liquid biopsy for early-stage cancer screenings, heightened demand for real-time cancer tracking, increased use in precision oncology, and escalating investments in research and development in the liquid biopsy field. During the forecast period, the market landscape will be shaped by emerging trends, including the use of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing technology, growth of multi-omics liquid biopsy platforms, enhancements in sensitivity and specificity of liquid biopsy, and the adoption of digital PCR for highly precise mutation detection.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are the Core Market Drivers Propelling Growth in the Breast Cancer Liquid Biopsy Industry?

The upsurge in incidents of breast cancer is predicted to spur the expansion of the breast cancer liquid biopsy market. Breast cancer, a cancer variant that originates in the breast cells, particularly in the lobules (the milk-producing glands) or ducts (channels conveying milk to the nipple), is on an upward trajectory. This is attributed to factors like genetic factors, hormonal imbalances, an aging population, alterations in lifestyle, obesity, alcohol intake, insufficient physical exertion, exposure to radiation, and environmental toxins. A breast cancer liquid biopsy plays a critical role in treatment by identifying circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, thus facilitating real-time disease monitoring. It is beneficial for gauging treatment response, recognizing resistance to therapy, and uncovering genetic alterations for specific therapies. For instance, the American Cancer Society, a US-based nonprofit organization committed to cancer research, education, advocacy, and patient support, anticipates the number of new breast cancer cases to escalate to 319,750 in 2025 from 313,510 cases in 2024. Consequently, the escalating breast cancer cases are encouraging the expansion of the breast cancer liquid biopsy market.

How Is the Breast Cancer Liquid Biopsy Market Segmented?

The breast cancer liquid biopsymarket covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Which Regions Are Driving the Next Phase of the Breast Cancer Liquid Biopsy Market Growth?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Breast Cancer Liquid Biopsy Industry?

Leading firms in the breast cancer liquid biopsy market are concentrating on the creation of novel products, including companion diagnostics, to facilitate personalized treatment strategies by pinpointing patients who stand to gain from specific treatments. The function of companion diagnostics is to use liquid biopsy technologies to identify biomarkers such as genetic changes, circulating tumor DNA (ctDNA), or protein expressions that signal responsiveness to treatment. For instance, Guardant Health Inc., a biotechnology company located in the US, was given approval by the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), which is a treatment for advanced or metastatic breast cancer patients with ESR1 mutations in January 2023. This approval empowers oncologists to apply the test for comprehensive genomic profiling to spot patients who could potentially benefit from this targeted therapy. It is the first time the U.S. Food and Drug Administration (FDA) has approved a Guardant Health product for breast cancer, broadening its contributions to precision oncology.

View the full report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

How Is the Breast Cancer Liquid Biopsy Market Defined and What Are Its Core Parameters?

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient’s blood or other bodily fluids. It provides valuable insights into the presence, progression, and genetic profile of breast cancer without requiring a traditional tissue biopsy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Breast Cancer Liquid Biopsy Market Size Changed, over the years?

Recent years have seen a swift expansion in the size of the breast cancer liquid biopsy market. Projected growth from $0.78 billion in 2024 to $0.90 billion in 2025, indicates a compound annual growth rate (CAGR) of 15.0%. Factors contributing to this historic period of growth include the progression in next-generation sequencing (ngs), a surge in the prevalence of breast cancer, an escalating demand for non-invasive diagnostic procedures, the increased adoption of personalized medicine and a rise in funding for cancer research.

How Much Will the Breast Cancer Liquid Biopsy Market Be Worth in 2029?

In the coming years, the market size for liquid biopsies for breast cancer is set to experience a significant surge. It’s projected to reach a value of $1.56 billion by 2029 representing a 14.7% compound annual growth rate (CAGR). The projected growth for the forecast period can be attributed to technological evolution in liquid biopsy tests, increased use of these tests in preliminary cancer screening, a growing need for constant cancer monitoring, an expansion in its use in precision oncology, and increasing investments in liquid biopsy R&D. The forecast period will also witness major trends such as the integration of AI in liquid biopsy assessment, progress in single-cell sequencing, the development of multi-omics liquid biopsy platforms, enhancements in the sensitivity and specificity of liquid biopsy, and the adoption of digital PCR for ultra-accurate mutation detection.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which is the Largest Company in the Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

What Are the Main Market Drivers in the Breast Cancer Liquid Biopsy Industry?

Anticipated growth in the breast cancer liquid biopsy market is due to the rise in breast cancer cases. A form of cancer that originates in the cells of the breast, specifically within the lobules or milk-producing glands or ducts which transport milk to the nipple, is known as breast cancer. Influencing factors for an increase in breast cancer cases include a genetic inclination, hormonal inconsistencies, the aging population, changes in lifestyle, obesity, alcohol intake, lack of exercise, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy aids the treatment process by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) present in the blood, thus providing real-time monitoring of the disease. Moreover, it assists in evaluating the treatment’s effectiveness, discerning resistance to therapy, and distinguishing genetic mutations that can be targeted for treatment. For example, the American Cancer Society, a nonprofit organization in the US that is dedicated to conducting cancer research, education, advocacy, and patient support, has predicted that there will be 319,750 new breast cancer cases in 2025 compared to 313,510 in 2024. Consequently, the rise in breast cancer cases is fuelling the growth of the breast cancer liquid biopsy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

How Is the Breast Cancer Liquid Biopsy Market Segments Structured?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Strategic Trends Are Transforming the Breast Cancer Liquid Biopsy Market?

Key businesses in the breast cancer liquid biopsy market are concentrating on the advancement of innovative products, including companion diagnostics. These are designed to support personalized treatment strategies by recognizing patients who may profit from specific therapies. Companion diagnostics employ liquid biopsy methods to identify biomarkers such as genetic disruptions, circulating tumor DNA (ctDNA), or protein manifestations suggestive of a response to treatment. For example, in January 2023, Guardant Health Inc., a biotech firm based in the U.S., obtained approval from the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy examination to be used as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant). This is a remedy for advanced or metastatic breast cancer sufferers who possess ESR1 mutations. This approval allows oncologists to utilise the test for thorough genomic profiling to identify patients likely to benefit from targeted therapy. This represents the first FDA approval for Guardant Health in the field of breast cancer, enhancing its role in precision oncology.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Global Regions Offer the Highest Growth in the Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

This Report Delivers Insight On:

1. How big is the breast cancer liquid biopsy market, and how is it changing globally?

2. Who are the major companies in the breast cancer liquid biopsy market, and how are they performing?

3. What are the key opportunities and risks in the breast cancer liquid biopsy market right now?

4. Which products or customer segments are growing the most in the breast cancer liquid biopsy market?

5. What factors are helping or slowing down the growth of the breast cancer liquid biopsy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model